South Korea drug regulator flags 949 illegal online listings for GLP-1 obesity drugs
Version 3: Another outlet has joined the coverage with the same figures, and the ministry's warnings on unlicensed overseas products, cold-chain handling and the lack of legal protection for buyers now appear across a wider set of reports; no new facts about the enforcement itself emerged.
In short
South Korea's Ministry of Food and Drug Safety said it caught 949 posts violating the Pharmaceutical Affairs Act while checking illegal online sales, brokering and advertising of GLP-1 obesity treatments, and asked the Korea Communications Standards Commission and other bodies to block access. Online sales and introductions to sales sites were the largest category at 716 posts (75.4%), followed by cafes and blogs at 129 (13.6%), SNS one-to-one chat guides at 72 (7.6%) and person-to-person secondhand trading at 32 (3.4%). The ministry warned the drugs are prescription-only, name-checked Wegovy and Mounjaro, and said overseas direct-purchase products may be counterfeit or defective with no legal protection for buyers.
Read the full story 2 min read
South Korea's Ministry of Food and Drug Safety said on October 6 that it identified 949 posts violating the Pharmaceutical Affairs Act while inspecting illegal online sales, brokering and advertising of GLP-1 obesity treatments, and said it asked the Korea Communications Standards Commission and other bodies to block access to them. Two business outlets said the check covered January 1 to September 30 of this year, while the official announcement referred to this year without giving dates. The official outlet named Mounjaro and Wegovy among the treatments involved. [ 1 , 2 , 3 , 4 , 5 , 6 ]
By type, online sales and introductions to sales sites were the largest category at 716 posts, or 75.4% of the total. Posts introducing or linking to sales sites through cafes and blogs followed at 129 posts (13.6%), guides to one-to-one chat accounts on social media at 72 posts (7.6%) and person-to-person secondhand trading at 32 posts (3.4%), according to the ministry. [ 1 , 2 , 4 , 5 , 6 ]
The ministry said GLP-1 obesity treatments are prescription-only drugs that must be administered at set doses and according to directions under a doctor's prescription and a pharmacist's medication guidance, so they should not be distributed or bought through overseas direct purchase or private transactions. One business outlet reported the ministry's view that such treatments are sometimes misused for cosmetic purposes, and another described how the drugs work by increasing insulin secretion according to blood sugar, suppressing glucagon and prolonging a feeling of fullness. [ 1 , 2 , 4 , 5 , 6 ]
The ministry warned in particular that overseas direct-purchase products have not been licensed in Korea, that their safety and efficacy have not been sufficiently verified and that their manufacturing and distribution processes cannot be confirmed, creating a risk of counterfeit or defective drugs. A ministry official said that if harm occurs during use it is difficult to receive recalls, compensation or other legal protection. [ 1 , 2 , 4 , 5 , 6 ]
The drugs also require cold-chain storage, refrigerated or frozen, and the ministry said they can deteriorate if proper temperatures are not maintained while being brought into the country, even if the product was distributed normally abroad. [ 1 , 2 , 5 , 6 ]
A ministry official said GLP-1 obesity treatments must be used under a domestic doctor's prescription and that the ministry will keep working to prevent consumer harm and maintain sound drug distribution. Another official said the ministry plans to continue inspecting online illegal sales, brokering and advertising of the treatments. One business outlet linked the enforcement to heightened public interest from a recent “obesity injection” boom. [ 2 , 5 ]
Why it matters
The action targets prescription-only obesity drugs that have drawn heavy public interest, and points to an online market where consumers may buy unverified products directly or from abroad. The ministry says such purchases carry health risks and leave buyers without recalls, compensation or other legal protection. What happens to individual sellers beyond the blocking request is not stated in the documents.
Key facts
- The Ministry of Food and Drug Safety said it identified 949 posts violating the Pharmaceutical Affairs Act during an inspection of illegal online sales, brokering and advertising of GLP-1 obesity treatments. [ 1 , 2 , 3 , 4 , 5 , 6 ]
- Online sales and introductions to sales sites were the largest category at 716 posts, or 75.4% of the total. [ 1 , 2 , 4 , 5 , 6 ]
- Cafe and blog posts introducing or linking to sales sites accounted for 129 posts (13.6%), SNS one-to-one chat account guides 72 posts (7.6%) and person-to-person secondhand trading 32 posts (3.4%). [ 1 , 2 , 4 , 5 , 6 ]
- The ministry said it requested that access to the posts be blocked, including through the Korea Communications Standards Commission. [ 1 , 2 , 4 , 5 , 6 ]
- The ministry said GLP-1 obesity treatments are prescription-only drugs that must be administered at set doses under a doctor's prescription and a pharmacist's medication guidance, and the official outlet named Mounjaro and Wegovy among the treatments involved. [ 1 , 6 ]
- The ministry said overseas direct-purchase products are not licensed in Korea, their safety and efficacy have not been sufficiently verified and their manufacturing and distribution cannot be confirmed, raising the risk of counterfeit or defective drugs. [ 1 , 2 , 4 , 5 , 6 ]
- The drugs require cold-chain (refrigerated or frozen) storage, and the ministry said they can deteriorate if proper temperatures are not maintained while being brought into the country. [ 1 , 2 , 5 , 6 ]
Confirmed by several sources
- The Ministry of Food and Drug Safety identified 949 posts violating the Pharmaceutical Affairs Act related to GLP-1 obesity treatments and requested that access to them be blocked. [ 1 , 2 , 3 , 4 , 5 , 6 ]
- Online sales and introductions to sales sites were the largest category, at 716 posts (75.4%), followed by cafe and blog posts at 129 (13.6%), SNS one-to-one chat account guides at 72 (7.6%) and person-to-person secondhand trading at 32 (3.4%). [ 1 , 2 , 4 , 5 , 6 ]
- The ministry said GLP-1 obesity treatments are prescription-only drugs that must be used according to a doctor's prescription and a pharmacist's guidance, and warned against overseas direct purchase or private transactions. [ 1 , 2 , 4 , 5 , 6 ]
- The ministry said overseas direct-purchase products are not licensed in Korea, have not been sufficiently verified for safety and efficacy and cannot be traced through manufacturing and distribution, so they may be counterfeit or defective. [ 1 , 2 , 4 , 5 , 6 ]
- The ministry said the drugs require cold-chain storage and may deteriorate if proper temperatures are not maintained during import. [ 1 , 2 , 5 , 6 ]
Still unclear
- What enforcement followed beyond the request to block access, such as whether sellers were referred for prosecution. The documents describe only the identification of the posts and the blocking request; no outlet reports charges or referrals.
- Whether any consumers reported harm from products sold through these posts. No document states that an injury or damage case was reported.
- Whether the 949 posts involve distinct sellers or overlapping accounts. The documents give a post count and a category breakdown but do not say how many sellers or accounts are involved.
- The exact inspection dates. Two business outlets give January 1 to September 30, another says January to September, while the official announcement says only “this year.”
What local media are saying
Timeline, local time
- The Ministry of Food and Drug Safety announces that 949 Pharmaceutical Affairs Act-violating posts for GLP-1 obesity treatments were caught and that blocking has been requested. [ 1 ]
- A business outlet reports the same figure and adds the January 1 to September 30 inspection period plus a description of how GLP-1 drugs work. [ 2 ]
- Another business outlet carries the 949-case figure in its headline. [ 3 ]
- A fourth outlet reports the figure, the category breakdown and the ministry's guidance on prescriptions. [ 4 ]
- A fifth outlet reports the case total and carries a ministry official saying online illegal sales and brokering will continue to be monitored. [ 5 ]
- A sixth outlet reports the figure and names Wegovy and Mounjaro, repeating the ministry's warning about unlicensed overseas products. [ 6 ]